Lung Cancer in the Very Young: Treatment and Survival in the National Cancer Data Base

Arnold, Brian N.; Thomas, Daniel C.; Rosen, Joshua E.; Salazar, Michelle C.; Blasberg, Justin D.; Detterbeck, Frank C.; Kim, Anthony W.

doi:10.1016/j.jtho.2016.03.023

Cited by 81 publications

(86 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancers such as breast cancer, colon cancer, and acute lymphoblastic leukemia are understood to present a distinct disease biology in patients diagnosed at a young age . In contrast, NSCLC in the young is a poorly studied clinical entity . It has been reported that 70 years of age was the median age for diagnosis of NSCLC and patients diagnosed younger than 50 years accounted for less than 5% of patients .…”

Section: Introductionmentioning

confidence: 99%

Comprehensive analysis of age‐related somatic mutation profiles in Chinese young lung adenocarcinoma patients

Yang

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

Background Lung adenocarcinoma in young adults is a rare entity with the oncogenic genetic alterations associated being poorly understood. In the present study, the effect of genetic alterations in lung adenocarcinoma patients diagnosed in young patients is reported. Methods Twenty young lung adenocarcinoma patients (age years: median: 33.5, range: 24‐36) were enrolled in the current study and 24 patients who were at common age of the disease onset (age years: median: 61.5, range: 52‐79) were selected for comparison. Paraffin sections of lung adenocarcinoma were analyzed using the whole‐exome sequencing platform. Results Similar number of somatic mutations per tumor were found in the young patients and their older counterparts. Although no age‐related differences were detected in the numbers of lung adenocarcinoma patients harboring well‐known gene variants, mutations in FRG1 and KMT2C were associated with a younger age especially after correcting for tobacco smoking and sex (FRG1: P = 0.027, KMT2C: P = 0.046). Five genetic variants showed higher alteration frequencies in young patients compared to the unclassified East Asian population, suggesting these mutations as disease‐related hereditary germline variants. Conclusions These results suggest different characteristics of lung adenocarcinoma between the young and the patients at common age of onset. Young patients with lung adenocarcinoma have a distinctly unique prevalence of oncogenic genetic alterations.

show abstract

Section: Introductionmentioning

confidence: 99%

Comprehensive analysis of age‐related somatic mutation profiles in Chinese young lung adenocarcinoma patients

Yang

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…It is worth noting that age has been recognized as a significant prognostic factor in some tumors. In non-small cell lung cancer, younger patients take advantage in overall and relative survival, particularly at earlier stage [12]. By contrast women with breast cancer aged 35 years or younger are recommended to adopt additional risk-reduction strategies after radical treatment [13].…”

Section: Introductionmentioning

confidence: 99%

Better cancer specific survival in young small cell lung cancer patients especially with AJCC stage III

et al. 2017

View full text Add to dashboard Cite

It has been reported that younger patients with non-small cell lung cancer (NSCLC) tend to have a better prognosis. Yet, few studies have focused on the clinicopathological characteristics and prognosis of young small cell lung cancer (SCLC), especially for patients with age < 50. In our study, we used Surveillance, Epidemiology, and End Results (SEER) population-based data and identified 16503 patients with SCLC including 711 patients aged < 50, 3338 patients aged 50–59, 5937 patients aged 60–69, 4649 patients aged 70–79 and 1868 patients aged ≥ 80 between 2010 and 2013. The Kaplan-Meier methods was used to develop the survival curve, and the results showed that the SCLC patients with aged < 50 tended to a better over survival (OS) and cancer specific survival (CSS) (all, P < 0.001). In addition, Cox regression model was used to analyze survival prognosis factors and perform subgroup analysis. The results showed that age was an independent prognostic factor for CSS (P < 0.001). Importantly, we found that for the patients with AJCC stage III subgroup, the age < 50 had apparent CSS benefit compared with any other age group (all, P < 0.01). Interestingly, for the patients with no surgery, radiation and no radiation subgroup, the age < 50 had no apparent CSS benefit only compared with age 50–59 (all, P > 0.05). In conclusion, our study demonstrated that the SCLC patients with aged < 50 tended had a better survival benefit, especially for patients with AJCC stage III.

show abstract

“…Specifically, younger patients (less than 50 years of age) with NSCLC have been reported to have better survival outcomes when compared to older patients [3,4]. In contrast, very little data have been reported with regard to young patients with SCLC.…”

Section: Introductionmentioning

confidence: 99%

Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry

Lara¹,

Brunson

Riess

et al. 2017

Lung Cancer

View full text Add to dashboard Cite

A B S T R A C TBackground: Small cell lung cancer (SCLC) is an often lethal disease that commonly occurs in older individuals with a history of heavy tobacco use. Limited epidemiologic and outcomes data are available on young SCLC patients aged less than 50 years of age. We assessed clinical variables related to cause specific survival (CSS) of young patients with SCLC. Methods: SCLC patients in the California Cancer Registry diagnosed between 1998 and 2012 were included. Primary outcome measure was CSS. Hazard ratios (HR) for CSS were calculated using Cox Proportional Hazards (pH) models for all ages & for patients < 50 years, adjusted for baseline variables: age, gender, stage, race, year of diagnosis, initial treatment, socioeconomic status (SES), and location (urban vs. rural). Results: We identified 22,863 SCLC patients, of which 975 were less than 50 years of age (4.2%). Most patients < 50 years of age were male (51%), white race (71%), and had stage IV disease (60%). A lower proportion of patients aged 50 years or younger was diagnosed in later years: from 40% in 1998-2002 to 24% in 2008-2012. For all SCLC patients, age less than 50 years was an independent predictor of improved CSS (HR = 0.82, p < 0.0001). Multivariate Cox pH models showed that in younger patients, female sex (HR = 0.81, p = 0.0045), Asian race (HR = 0.57, p = 0.0075), and rural residence (HR = 0.75, p = 0.042) were associated with better CSS, among other variables. Conclusions: In patients with SCLC, age less than 50 years was an independent predictor of improved CSS. Baseline clinical variables associated with better CSS were identified. These results have potential clinical applications.

show abstract

Lung Cancer in the Very Young: Treatment and Survival in the National Cancer Data Base

Cited by 81 publications

References 24 publications

Comprehensive analysis of age‐related somatic mutation profiles in Chinese young lung adenocarcinoma patients

Comprehensive analysis of age‐related somatic mutation profiles in Chinese young lung adenocarcinoma patients

Better cancer specific survival in young small cell lung cancer patients especially with AJCC stage III

Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry

Contact Info

Product

Resources

About